SCHEMBL5541399

SCHEMBL5541399

Cc1ccc2c(c1)C(C)(C)C(=O)N2C(C)C

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
GLA P06280 1/20 0.49
MAPT P10636 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 4/20 0.41
TP53 P04637 1/20 0.40
POLB P06746 2/20 0.40
PKM P14618 1/20 0.39
CNR1 P21554 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
SLC6A4 P31645 2/20 0.38
SLC6A2 P23975 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
MARK3 P27448 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539575 0.84 MAPT (0.46) MEN1KMT2AGLAMAPTKDM4E
SCHEMBL27145498 0.82 SLC6A4 (0.41) MEN1KMT2AGLAMAPTKDM4E
SCHEMBL5541395 0.82 MARK3 (0.36) MEN1KMT2AGLAALDH1A1TP53
SCHEMBL27300504 0.82 SLC6A4 (0.37) MEN1KMT2AGLAMAPTKDM4E
SCHEMBL5010350 0.82 ALDH1A1 (0.39) MEN1KMT2AGLAALDH1A1SLC6A4
SCHEMBL4961767 0.81 SLC6A4 (0.54) MEN1KMT2AHTTALDH1A1TP53
SCHEMBL21218098 0.79 MARK3 (0.36) MEN1KMT2AGLAKDM4EALDH1A1
SCHEMBL12659870 0.78 MAPT (0.46) MEN1KMT2AMAPTALDH1A1POLB
SCHEMBL5539734 0.77 MEN1 (0.56) MEN1KMT2AMAPTKDM4EHTT
SCHEMBL7703988 0.76 RARA (0.57) MEN1KMT2AGLAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MEN1 3295/4885KMT2A 4267/4885GLA 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.